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                                                     INTRODUCTION  
 
The ocular blood flow (Pulsatile Ocular Blood Flow – POBF) varies with the systole and 
diastole, and hence the intraocular pressure (IOP) too varies with the cardiac cycle.  Ocular Pulse 
Amplitude (OPA) is the fluctuation of IOP with the heart rate (cardiac cycle), which is equal to 
the difference between systolic and diastolic IOP (1). OPA is an indirect indicator of the 
choroidal perfusion and reflects the ocular blood flow corresponding to the pulse as a function of 
time. These pulsatile variations in IOP are thought to be caused by the blood volume that is 
pumped into the eye, mainly the choroidal bed during each cardiac cycle. OPA has been studied 
in normals (2) as well as in patients with glaucoma (3-5) and vascular disorders (6-9). A 
reduction of the blood flow may cause hypoxia and further cell death and therefore may also 
initiate diseases like normal tension glaucoma and diabetic retinopathy.  
The Dynamic Contour Tonometer (DCT; Swiss Micro technology AG, Switzerland) represents a 
potential new technology for measuring choroidal blood flow indirectly & non-invasively. 
Moreover, DCT allows simultaneous recording of IOP and OPA and it can be mounted on a slit 
lamp. OPA is an indirect indicator of choroidal blood flow. Indocyanine green angiography 
(ICG) was the only method available to assess choroidal perfusion and related abnormalities till 
recently (10). Increased arm-to-choroid circulation time and delayed intrachoroidal circulation 
times suggest severe choroidal hypoperfusion (11). Animal studies have shown that even brief 
pressure on the retinal pigment epithelium (RPE) and choroid causes immediate reduction in 
flow through choroidal vessels as determined by ICG (12). 
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Choroidal perfusion is found to be reduced in diabetic patients (13) and anatomic and histologic 
studies (14) prove the existence of diabetic choroidopathy. In patients with end stage renal 
disease who are hemodialyzed, the onset of choroidopathy depends on an early arteriolar 
atherosclerosis of the choroidal membrane, probably secondary to chronic renal failure rather 
than to hemodialysis (15). Choroidal perfusion has been found to be reduced in patients with end 
stage renal disease as determined by ICG (16-17).  However ICG is an invasive procedure.  The 
spectral-domain OCT, a new non invasive investigation was found to be able to image the 
choroid better because it offers higher resolution and faster acquisition of A-scan data in 
assessing the health of the choroid (18). OCT, on the other hand can image choroid only at the 
macula.  
DCT is a non-invasive method which can measure OPA. OPA could give indirect evidence to the 
choroidal perfusion and may be used as an accurate non invasive tool to assess ocular perfusion 
especially in patients with suspected compromise in perfusion. This is particularly important in 
patients with end stage renal disease where indocyanine green dye angiography is 
contraindicated. Renal failure not only alters the renal elimination, but also accelerates the non-
renal disposition of drugs that are extensively metabolized by the liver. Renal failure impairs the 
liver uptake of drugs and organic anions, such as bromosulphophthalein, ICG, and thyroxine, 
where organic anion transport polypeptides are the major transporters (19). 
 Till date there are no studies which have measured OPA in non diabetic patients with end stage 
renal disease. Studies on diabetic retinopathy and OPA have shown varying results. 
Hypertension and end stage renal disease are associated with choroidopathy (20-21). Since ICG 
angiography to look at choroidal perfusion is contraindicated in end stage renal disease, 
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measurement of OPA using DCT will provide us with a simple noninvasive test to detect the 
choroidal perfusion in these patients. It could also be helpful in looking at the choroidal 
perfusion after renal transplantation. 
 In this study we postulate that measurement of OPA can be used as a surrogate to assess the 
choroidal perfusion in patients with end stage renal disease. Subsequent studies on subjects with 
early nephropathy may give us a clue as to whether OPA measurement can be used for early 
detection of nephropathy which can go undetected especially in those with no retinopathy. 
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                      AIMS AND OBJECTIVES 
 
 
AIMS: 
1. To measure the Ocular Pulse Amplitude (OPA) in non diabetic patients with end stage renal 
disease (ESRD).   
2. To compare the OPA in patients with ESRD with that of age matched normals. 
 
OBJECTIVES: 
1. To measure the OPA in non diabetic patients with end stage renal disease and normal individuals 
using Dynamic Contour Tonometry.  
2. To determine whether there is a statistically significant difference between OPA between the two 
groups. 
3. To determine the correlation between OPA and other parameters like, age, gender, intraocular 
pressure, blood pressure and serum creatinine levels. 
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                        LITERATURE REVIEW 
Ocular perfusion and Choroidal perfusion: 
Perfusion pressure which is an important factor in ocular blood flow is the difference between 
the mean blood pressure and the intraocular pressure (IOP). The ocular blood flow will be 
significantly reduced with decrease in the perfusion pressure (1) and this may lead on to ocular 
ischemia and hypoxia. Choroidal venous pressure exceeds the IOP slightly and arteriovenous 
pressure gradient is the driving force for the choroidal blood flow.  The difference between the 
mean arterial pressure in the ophthalmic artery and the IOP gives the choroidal perfusion 
pressure (1) 
Measurement of ocular perfusion pressure has been described by Kim et al., (22) and Zheng et 
al., (23) in their studies. All subjects had their blood pressure measured twice to establish stable 
hemodynamic condition and averaged. Mean arterial blood pressure (MAP) was calculated using 
the formula, MAP= DBP + 1/3
 
(SBP – DBP) where DBP is the diastolic blood pressure and SBP 
is the systolic blood pressure. Mean ocular perfusion pressure (OPP) was calculated using the 
equation, OPP = 2/3 (MAP – IOP).  
Kim et al., investigated the correlation between choroidal thickness and ocular perfusion pressure 
in 64 young healthy subjects. They found that subfoveal choroidal thickness in eye with < 6 D 
myopia measured with the help of enhanced depth imaging optical coherence tomography study 
correlated significantly (p = <0.001) with OPP with a mean subfoveal choroidal thickness of 
307.03 ± 91.27 microns and mean OPP of 44.18 ± 5.49 mm Hg. Zheng et al., described the 
distribution of ocular perfusion pressure and its relationship to open angle glaucoma. 3261 
15 
 
persons were included in the study out of which 131 cases had open angle glaucoma and they 
concluded that low diastolic blood pressure, low mean ocular perfusion pressure (MOPP) and 
low diastolic perfusion pressure (DPP) are independent risk factors for open angle glaucoma.   
 
Ocular Pulse Amplitude (OPA): 
Intraocular pressure (IOP) varies with the cardiac cycle. This variation occurs because ocular 
blood flow (Pulsatile Ocular Blood Flow –POBF) varies with the systole and diastole of the 
cardiac cycle (1). The OPA is the difference between the minimum and maximum values of the 
pulsatile IOP wave contour. It represents the difference between mean systolic and mean 
diastolic IOP. These pulsatile variations in IOP are thought to be caused by the blood volume 
that is pumped into the eye mainly the choroidal bed during each cardiac cycle. OPA is thus an 
indirect indicator of the choroidal perfusion. OPA has been studied in normals (4) as well as in 
patients with glaucoma (24-27) and vascular disorders (28-30). Changes in OPA following 
treatment of glaucoma also have been noted (31-34). 
OPA in normal eyes:  
In earlier studies with pneumotonometry (2), the mean OPA was found to be 1.5 ± 0.11 mmHg 
and with ocular blood flow analyzers (2), the OPA ranged from 2.2±0.8 to 3.0±0.92mm Hg. In a 
study of 148 healthy participants (223 normal eyes) using Dynamic contour tonometry (DCT), 
Kaufmann et al., (2) found a median OPA value of 3.0mmHg (10
th
 -90
th
 percentile range, 1.8-
4.3mmHg) .The OPA difference in the 75 pair of eyes examined ranged from 0.0-2.5mm Hg 
(median 0.4 mmHg, 10
th
 -90
th
 percentile range, 0.1-1.2mmHg).There was no statistically 
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significant difference in the OPA between right and left eyes. They found no significant 
correlation between OPA and CCT, corneal curvature, anterior chamber depth, age or gender. 
There was a positive correlation between OPA and IOP (0.12 mm Hg/1 mm Hg of IOP) and a 
negative correlation between OPA and axial length (0.27mm Hg/ 1 mm of axial length).  
Stalmans et al., (27) also found that OPA is influenced by IOP even after making the corrections 
for CCT. They included 28 patients with normal tension glaucoma, 19 patients with primary 
open angle glaucoma and 22 age-matched healthy individuals in the study. Patients underwent 
CCT measurements and 2 consecutive IOP measurements with Goldmann applanation tonometer 
and DCT. They found that the OPA increased with increase in IOP with a p value of 0.002 by 
Goldmann applanation tonometry and with a p value of < 0.0001 by DCT. They also found that 
OPA is reduced in normal tension and open angle glaucoma patients compared to normal 
individuals and concluded that IOP influences OPA whereas corneal thickness does not influence 
OPA. In a smaller study on 19 healthy subjects, Hoffmann et al., (35) described a mean OPA 
value of 3.08± 0.92 mmHg. 
In another study of 52 eyes of 28 normal healthy adults, Purjavan et al., (36) obtained a mean 
OPA of 2.2 +/- 0.7 mmHg (range: 1-3.4 mmHg). The mean amplitude of diurnal OPA 
fluctuations was 0.4 mmHg. There was no significant difference in the mean OPA values at each 
time of the diurnal curve. There was positive correlation between OPA and IOP as measured 
using Goldmann Applanation Tonometry (GAT) (r = 0.31, P < 0.0001) and DCT (r = 0.49, P < 
0.0001). There was no correlation with either blood pressure or age. OPA values of both eyes of 
the same individual were highly correlated (r = 0.89, P < 0.0001). 
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OPA in vascular disorders:  
Significant asymmetry in OPA has been documented in patients with vascular stenosis (15, 16) and 
arteriovenous fistulas (8, 9).  Most studies in diabetics (37-41) have looked into the POBF and not 
measured OPA directly. Ocular blood flow has been found to be near normal in mild- moderate NPDR 
and high in those patients with PDR.  A study by Greishaber et al., (6) which looked at the relationship 
between OPA and systemic blood pressure measurements, showed no correlation between OPA and 
systolic or diastolic blood pressures or their amplitudes. They found that OPA depends strongly on the 
time-course of cardiac contraction.  
In a study done by Golnik et al., (8) patients were divided into 3 groups in which, the first group had 
normal individuals, the second group had either unilateral or asymmetric orbital disease and the third 
group had angiographically proven cavernous sinus arteriovenous fistulas. OPA was measured using a 
pneumotonometer. They found that the patients in group 3 had higher OPA (p<0.001) compared to the 
other groups and successful transvascular embolization of the cavernous sinus arteriovenous fistula 
normalized the OPA. In another study done by Kaufmann et al., (9) OPA was found to be 4.38+/-
1.23mmHg in the right eye and 9.57+/-2.71 mmHg in the left eye in patients with dural cavernous sinus 
arteriovenous fistula. After transvenous embolization OPA was found to be 2.84-0.60mmHg in the 
right eye and 1.88-0.29mmHg.  
Savage et al., (37) compared the POBF of diabetic patients with severity of retinopathy with that 
of normal individuals. They did a masked cross sectional analysis with 77 diabetic subjects and 
66controls. Of these 13 patients had mild or no retinopathy, 36 had moderate to severe 
retinopathy and 28 had proliferative diabetic retinopathy (PDR) who were previously treated 
with pan retinal photocoagulation. Using Langham pneumotonometry, POBF in the right eye 
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was measured. They concluded that POBF is unaffected in early diabetic retinopathy whereas it 
increases in patients with moderate to severe NPDR. Patients with PDR who have undergone 
laser treatment showed a significant decrease in POBF and the difference between the 4 groups 
was statistically significant (p<0.0001). 
Using laser doppler flowmetry, Nagaoka et al., (41) determined choroidal blood flow in the 
foveal region in 70 patients with type 2 diabetes and 36 age and sex matched healthy subjects. 
Patients were classified into 3 groups, one group with no diabetic retinopathy, and second group 
with non proliferative diabetic retinopathy without macular edema (NPDR-MO) and a third 
group with non proliferative diabetic retinopathy with macular edema (NPDR+MO). They found 
that the choroidal blood flow in the foveal region with patients with NPDR+MO group was 
lower than that in NPDR-MO group and this indicated that the choroidal blood flow in the foveal 
region may decrease in the early stage of diabetic retinopathy and can worsen in presence of 
macular edema. 
OPA in glaucoma: 
Kniestedt et al., (25) studied 406 patients which included ocular hypertensives (OHT), glaucoma 
suspects (GS), open angle glaucoma (OAG) {including primary open angle glaucoma (POAG), 
normal tension glaucoma (NTG), pseudoexfoliation glaucoma (PEXG), pigment dispersion 
glaucoma (PDG), congenital glaucoma (CG) and juvenile glaucoma( JG).}, angle closure 
glaucoma (ACG) and mixed mechanism glaucoma (MMG).  Eyes studied included those which 
had undergone cataract surgeries, filtering surgeries as well as eyes on medical treatment for 
glaucoma. OPA was statistically significantly higher in the subgroups of OHT and MMG and 
statistically significantly lower in the NTG and GS subgroups (p=0.024).  
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Punjabi et al., (42) studied the IOP and OPA in 906 eyes of 501 adults.  The study included five 
groups- POAG, NTG, PEXG, OHT and NC (normal controls).  OPA was found to be highest in 
OHT (3.61 mmHg) and lowest in the control group (2.86 mmHg) and significantly increased 
with IOP in all groups. 
Stalmans et al., (27) studied patients with NTG (n=28), POAG (n=19) and age matched healthy 
controls (n=22).The OPA in the three groups were 2.3 ± 0.8, 2.6 ± 1.3, 3.4 ± 1.6 mm Hg. They  
found a clearly statistically significant difference in OPA values between healthy and NTG (p= 
0.002/0.006) and a borderline significant difference between healthy and POAG ( p= 
0.053/0.13), but no significant difference between NTG and POAG (p=0.35/0.61) concluding 
that OPA is lower in glaucoma patients as compared to healthy individuals.  
Kawabata et al., (4) studied OPA in 66 patients with NTG, 52 patients with POAG, 42 patients 
with OHT and 68 normal controls. The OPA in NTG was significantly lower than in normal 
controls (p<0.05).   
 
Methods of measurement of ocular blood flow: 
Pneumotonometric measurement of pulsatile ocular blood flow: 
A commercially available blood flow measurement system known as OBF system 3000 by OBF 
Labs, Malmesbury, UK is used to determine the pulsatile ocular blood flow (43). This system 
measures with a pneumatic applanation tonometer and measures ocular pressure changes caused 
by the rhythmic filling of the intraocular vessels as shown in Figure 1. 
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Figure 1: Pulsatile inflow of blood into ocular arteries and non pulsatile outflow via ocular veins 
 
 
 
Pulsatile ocular blood flow is calculated from the variation of IOP with time based on a 
theoretical model of eye. The theoretical model is a hydrodynamic model which is based on the 
assumption that inflow of blood into ocular arteries is pulsatile and outflow from the ocular veins 
are non pulsatile. It is also based on the assumption that ocular volume changes can be detected 
from changes in IOP based on a standard ocular rigidity function. The calculation of pulsatile 
ocular blood flow is determined by the five pulses that are closest to each other in IOP beat to 
beat variation.  
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Ocular blood flow analyzer:  
It is a comprehensive diagnostic test which uses a process known as pneumoplethysmography. 
The commercially available ocular blood flow analyzer by Paradigm Medical industries uses an 
electronic pneumatic tonometer capable of measuring and recording the IOP at a rate of 200 
times per second over a period of 5-15 seconds (44). 
 A sterilized single use per patient probe which have an integral membrane that isolates the 
cornea from the internal pneumatic operation of the blood flow analyzer is used. The pulsatile 
ocular blood flow is derived from IOP measurements got with pneumatic tonometer and with the 
help of mathematical equations that link IOP to ocular volume change and volume flow.  
In a single cardiac cycle, the pulsatile ocular blood flow rises to a peak value at systole rapidly 
and then falls slowly to a minimum value of diastole. The average pulsatile ocular blood flow is 
got by the ocular blood flow curve as the average of the inflow during each pulse multiplied by 
the number of pulses per second.  Six test parameters are taken by the machine per eye including 
IOP, pulse amplitude, systole and diastole duration, pulse rate and ocular blood flow.  
Ocular blood flow reference chart is as shown below in Figure 2. 
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Figure 2: Ocular blood flow reference chart 
 
 
Dynamic Contour Tonometry: 
It is based on the principle that when a hypothetical corneal shape is achieved, a measurement of 
pressure which is surface independent can be achieved. The force distribution required to gently 
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fit the corneal surface to the hypothetical contour counterbalances the force distribution 
generated by the IOP (45-49). A pressure sensor that is centrally and concavely embedded into 
the tonometer tip precisely measures the pressure of the eye transcorneally. In a functioning DCT 
device, we assume that the cornea is a spherical shell which is made up of a material that resists 
stretching and is fairly flexible to bending deformations. The rigidity forces due to bending and 
buckling are not totally without effect, but they are negligible for practical purposes.        
To achieve an ideal device for transcorneal pressure measurement, we need to imagine a 
container that is filled with casting resin surrounding an entire globe. This is as shown in the 
figure below (Figure 3). 
Figure 2:  A container filled with casting resin surrounding the entire globe 
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 In this closed system, the resin around the eye is under a pressure ‘p’. This pressure around the 
resin is equal to the pressure inside the eye. The forces ‘F’ generated by the IOP ‘p’ act 
perpendicularly through the cornea and sclera and uniformly on the bulbar-resin interface. These 
forces are also counterbalanced by the external forces caused by the pressure in the resin. The 
eye floats in the resin in total relaxation. If a pressure sensor with identical surface shape is 
replaced for a small part of the wall, the sensor measures a pressure ‘p’ that exactly corresponds 
to the true IOP ‘P’ and the same concept applies if the surrounding sphere is only partial. So, if 
we take a cylindrical tip that duplicates for a part of the sphere, with a surface contour identical 
to the one of the whole sphere (Figure 3), the force distribution and area will also be identical 
(45).  
Figure 3: Dynamic contour tonometer  
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The distribution of the external interface forces between the tip and the cornea equals the 
distribution of the internal forces that are generated by the intraocular pressure. Changes in the 
appositional force, the corneal radius and thickness, or other corneal properties usually alter the 
diameter’d’. But these factors do not affect the force distribution, provided the diameter of the tip 
is larger than‘d’ and the diameter of the pressure sensor is smaller than‘d’.            
In the Pascal DCT device, the contoured tonometer tip has a curvature radius of 10.5 mm and a 
contact surface diameter of 7.5 mm. The pressure-sensitive area in the center of the contour 
surface has a diameter of 1.2 mm. The pressure signal from the sensor is sampled and digitized at 
a 100 Hz sampling rate. A built-in microprocessor provides IOP and OPA values computed from 
the pulse curve thus obtained (11). (Figure 4)    
 
Figure 4: Ocular pressure curve with systolic / diastolic components. 
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The tonometer head with a contoured contact surface containing the sensor tip is applied to the 
centre of the patient’s cornea with a small, constant force. The pressure sensor built into the 
contact surface of the sensor tip generates an electrical signal which is proportional to the IOP. 
As an audible feedback, the main unit generates the audio signal whose pitch is proportional to 
the IOP detected. The higher the IOP, the higher will be the pitch. The pressure signal is detected 
for a period of about 5 seconds corresponding to approximately 5 to 10 heart beats.  
Pascal software computes IOP and its variation (modulation) caused by the cardiac pulsation 
(OPA) from the pressure dependent electrical signal and from the signal level after the interrupt. 
The signals are stored and processed in the main unit and numerical results (IOP, OPA and Q - 
quality factor) are displayed on an LCD display screen as shown in Figure 4. The information 
can be directly transferred to the computer for storage of the data including a recording (graph) 
of the variation in IOP during the cardiac cycle. 
 
Figure 4: 
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Indocyanine Green Angiography (ICG): 
In 1960, Fox and Wood described the physical and physiological properties of Indocyanine green 
(C43H47N2O6S2Na). It is a water soluble tricarbocyanine dye of molecular weight 775. It is highly 
protein bound and it does not readily escape from the choriocapillaris.  It absorbs near infrared 
portion of the spectrum at 805nm and reflects at 835nm. These special characteristics help the 
RPE to render invisible and facilitate visualization of the choroid through hemorrhage or other 
pigmentary deposits in the retina or RPE (50-52).  
ICG has excellent penetration of the RPE, macular xanthophyll, other ocular pigment and even 
blood, which allows superior viewing of the choroidal vasculature. Visualization through media 
opacities is improved as longer wavelengths undergo less scatter than shorter wavelengths. 
Approximately 98% of circulating ICG is bound to various serum proteins like albumin and -
lipoprotein. The dye's apparent poor penetration of capillary fenestrations in the choriocapillaris 
is due to this preferential binding to high-molecular-weight lipoproteins and this tendency of 
ICG to remain intravascular helps in the visualization of the choroidal vasculature (52). Similar 
to intravenous fluourescein angiography protocols, for ICG angiography, 12.5 to 50 mg or 
approximately 25mg of ICG dye in the manufacturer's diluent is administered intravenously in a 
bolus fashion. After intravenous injection, ICG is rapidly eliminated by the liver and minimal 
uptake in the peripheral tissues. ICG is not chemically altered in the liver. It has also been 
recovered in the bile unchanged. Normal ICGA has 3 phases (54-56). 
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Early phase: 
This involves the period from the first appearance of ICG dye in the choroidal arterial circulation 
to the point of maximal ICG choroidal hyperfluorescence, all of which occurs within the first 
minute after the injection of dye. During this phase, both medium and large choroidal arteries 
and veins are well visualized beneath the hyperfluorescent retinal vasculature whereas individual 
choriocapillaris cannot be distinguished. The area surrounding the middle and large choroidal 
vessels appears hypofluorescent and this pseudohypofluorescence is due to the volume of blood 
in the choriocapillaris over the larger vessels. 
Middle phase:  
This starts 6 to 15 minutes after injection of ICG. A nearly homogeneous, diffuse choroidal 
fluorescence emerges and so the choroidal veins become less distinct and the fluorescence from 
the retinal vessels also begins to attenuate. Lesions that demonstrate abnormal hyperfluorescence 
on ICGA starts to stand out in contrast to the fading surrounding normal background 
fluorescence during this phase. 
Late phase:   
It starts beyond 18 to 30 minutes when all details of normal retinal and choroidal vessels are lost 
as the hyperfluorescence fades even further. The choroidal vessels could be seen now as 
hypofluorescent channels, retinal vessels are no longer visible, and the optic nerve head is dark. 
Any abnormal hyperfluorescent lesions are seen with maximal contrast. 
Images are usually obtained at several-second intervals until the retinal circulation and choroidal 
one are maximally hyperfluorescent. Then the images are taken at approximately 30 to 60 
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seconds interval for the first few minutes of the study so as to capture images through the early 
phase of the angiogram. Further images are taken between 8 and 12 minutes for the middle 
phase, and then between 18 and 25 minutes for the late phase. 
Indications for ICGA:   
ICGA has been used in the diagnosis and management of exudative age related macular 
degeneration (ARMD), choroidal based tumours, to study conditions like central serous 
chorioretinopathy (CSCR), acute posterior multifocal placoid pigment epitheliopathy 
(APMPPE),multiple evanescent white dot syndrome (MEWDS), pathological myopia, Vogt 
Koyanagi Harada syndrome (VKH) and angioid streaks.  
Side effects of ICG: 
Fox and Wood have reported that there were no untoward effects seen in over 1000 patients who 
underwent cardiac function tests using ICG. In another large series of over 240000 intravenous 
injections of ICG, four patients experienced adverse reactions with one mortality. ICG is 
dissolved in a solvent which contains sodium iodide to prevent recrystallisation when given IV 
and the iodine content can cause allergic reaction. Inadvertent subcutaneous injection can cause 
skin discoloration for several weeks (53).  
 Absolute contraindications of ICG are iodine or shell-fish allergy and previous allergy to ICG. 
Hemodialysis (50), liver disease, allergic diathesis, pregnancy and end stage renal disease (51) 
are relative contraindications. 
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Chronic Kidney Disease (CKD):  
Chronic kidney disease is defined as abnormalities of kidney structure or function which is 
present for more than 3 months with implications on health (57). To diagnose CKD, either of the 
following should be present for more than 3 months: (57) 
I. Markers of kidney damage: One or more of the following:  
1) Albuminuria {Albumin excretion ration (AER) ≥ 30mg/24 hours; Albumin creatinine 
ratio (ACR) ≥ 30mg/g  [ ≥3mg/mmol]} 
2) Urine sediment abnormalities 
3) Electrolyte and other abnormalities due to tubular disorders 
4) Histological abnormalities  
5) Structural abnormalities detected by imaging 
6) History of kidney transplantation 
II. Decreased Glomerular Filtration Rate (GFR):GFR < 60ml/min/1.73m² (GFR categories 
G3a – G5) 
           According to GFR categories, chronic kidney disease is divided into 6 categories from 
G3a to G5. The patients who come under G5 category is called as end stage renal disease 
patients or kidney failure patients who are on dialysis. They have a GFR of < 15 ml/min/1.73m².  
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Ocular findings in patients with end stage renal disease (ESRD): (58-75) 
1) Intraocular pressure: Studies which measured IOP in patients with ESRD show conflicting 
results. Levy et al., in a review article found that various studies showed different 
conclusions on the effect of hemodialysis on IOP (59). Tobvin et al., (60) measured IOP at 
the beginning, end and 1 hour post dialysis in 19 chronic hemodialysis patients. They found 
that 7 out of the 19 patients had an increase in IOP. Nongpiur et al., (61) measured IOP in 
3280 Malay adults aged 40 to 79 years living in Singapore and found that there is an increase 
in IOP with CKD patients. Hojs et al., (62) did not find any difference in IOP before and 
after hemodialysis. De Marchi et al., (63) measured IOP in 55 patients on hemodialysis and 
found that there was no change in IOP in 44 patients, a rise in IOP in 10 patients and a 
decrease in IOP in 4 patients. Another study done by Tokuyama et al., (64) IOP of 32 
patients with chronic renal failure on hemodialysis were measured and they found that there 
was a decrease in intraocular pressure post hemodialysis. 
2) Corneal and conjunctival abnormalities:  Patients with ESRD can develop irritable scratchy 
eyes which are most often due to non specific inflammation which occurs in the conjunctiva 
(65). Disturbances in calcium phosphate metabolism leads to calcium salt deposits especially 
when the calcium phosphate product is elevated and this will cause subsequent congestion of 
episcleral vessels with local inflammation. ESRD patients will have blink reflex 
abnormalities, decreases tear break up time (TBUT) and decreases goblet cell numbers (66) 
High levels of Vitamin A are also found to cause dry eyes and squamous metaplasia in ESRD 
(67). 
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3) Band keratopathy: It can occur due to precipitation of calcium salts on the corneal surface. 
Tears and aqueous humour contain calcium and phosphates. Normally, evaporation of tears 
concentrates these solutes and increases the tonicity of tears. In ESRD, there is elevated 
serum calcium or serum phosphate which can drive the solution to precipitate. Also the 
elevation of the surface pH out of the physiologic range changes the solubility product and 
causes precipitation (68).  
4) Cataract formation:  There is limited information regarding the direct relationship between 
ESRD and cataracts. Most patients with ESRD have other comorbodities that are associated 
with increased risk for cataracts like advanced age, diabetes, hypertension, corticosteroids, 
ultraviolet light exposure and hyperparathyroidism. A hypothesis for ESRD was postulated 
that urea enters the lens prior to dialysis due to high blood urea levels. This is followed by a 
rapid decrease in levels during dialysis. This causes osmotic shifts that are repeated with 
every dialysis cycle, eventually leading to the development of an osmotic cataract. Increased 
oxidative stress that is common in ESRD patients may also contribute to cataract formation 
(69).  
5) Retinal detachment (RD): Some studies have suggested that uremia and dialysis cause 
changes in serum osmolarity and subsequent fluid shifts into the sub-retinal space with focal 
dehiscence in the pigment epithelium (70). Some other studies have hypothesized that 
increased chorio-capillary permeability allows larger molecules, like fibrinogen, to exit into 
the subretinal space causing exudative RD (71). 
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6) Macular edema:  In patients with ESRD, when macular thickness was measured by optical 
coherence tomography in patients with macular edema, macular thickness was significantly 
decreased by hemodialysis (72).  
7) Optic neuropathy: In ESRD patients, ischemic optic neuropathy is probably caused by 
significant intra-dialytic hypotension and may be exacerbated by concomitant anemia and 
decreased oxygen carrying capacity (73). However, in some patients, the increase in 
hematocrit and blood viscosity that occurs during dialysis and ultrafiltration can result in 
decreased retinal blood flow and an increased risk for ischemia. Drug-associated optic 
neuropathy has also been reported in patients receiving deferoxamine or OKT3 treatment 
(73).  
Patients with end stage renal disease are at a risk for developing eye disease. The 
microangiopathic abnormalities are similar to kidney and eye. Hence eye is considered a window 
to the diagnosis of kidney disease. Ocular fundus examination gives a lot of information about 
the cause of renal failure of which diabetic retinopathy is the probably the most significant. 
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                       MATERIALS & METHODS 
 
Study Design:  
This is a prospective, cross sectional, observational study. The exposed group consisted of 
patients with end stage renal disease on haemodialysis. Age matched individuals with no 
systemic illnesses formed the non-exposed group. 
Selection Criteria:    
Patients with end stage renal disease on haemodialysis were recruited from the Department of 
Nephrology, Christian Medical College, Vellore. Age matched subjects were selected from 
patients who came for ophthalmic evaluation to the Department of Ophthalmology. Patients 
fulfilling the inclusion and exclusion criteria were included in the study. 
Institutional Review Board (IRB) approval: 
The study protocol was approved by the IRB which constituted members outside the institution 
as per ICMR guidelines required for any study conducted in the institution (Annexure III - IRB 
approval).  The same way Ethical committee approval was also obtained (Annexure III - ethics 
committee approval)  
(Reference to IRB minutes number 8167 dated 09/01/2013) 
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Participants:  
The study was conducted in the Department of Ophthalmology, Christian Medical College, 
Vellore, from January 2013 to October 2013.  
 
Inclusion criteria for exposed: 
1) Patients with end stage renal disease referred from the dialysis unit. (According to 
glomerular filtration rate (GFR) categories, chronic kidney disease is divided into 6 
categories from G3a to G5 and the patients who come under G5 category with a GFR of 
< 15 ml/min/1.73m² is known as end stage renal disease patients or kidney failure 
patients who are on dialysis)  
2) ≥ 18 years of age. 
3) Non diabetic patients as defined as Fasting plasma glucose (FPG) ≤ 126 mg% with no 
calorie intake for at least 8 hours prior according to American Diabetes Association 
(ADA) guidelines. 
4) DCT OPA readings with Quality factor of 1 or 2. 
5) Willingness to give informed consent.(Annexure II) 
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Inclusion criteria for non-exposed: 
1) ≥ 18 years of age. 
2) Systolic BP < 120 mm Hg and diastolic BP < 80 mm Hg without any anti hypertensive 
medications according to Joint National Committee on prevention, detection, evaluation 
and treatment of high blood pressure (JNC7) guidelines. 
3) Fasting plasma glucose (FPG) ≤ 126 mg% with no calorie intake for at least 8 hours prior 
without any anti diabetic medications according to American Diabetes Association 
(ADA) guidelines. 
4) DCT OPA readings with Quality factor of 1 or 2. 
5) Willingness to give informed consent. (Annexure II) 
Exclusion criteria for exposed and non-exposed: 
1) Patients with glaucoma (IOP > 24 mm Hg or suspicious discs). 
2) History of transient ischemic attacks or cerebrovascular accidents. 
3) Patients with any corneal pathology with preclude the accurate measurement of OPA 
using DCT. 
4) Patients with vascular disorders like coronary artery disease (CAD), carotid stenosis, 
carotidocavernous fistulas and autoimmune disorders. 
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Methods: 
Measurement of OPA: 
Ocular Pulse Amplitude (OPA) was measured using Pascal’s Dynamic contour tonometer. The 
Pascal DCT (Picture 1, Annexure IV) (Model: Ziemer S Ophthalmology, SMT Swiss Micro 
technology 2005), like Goldman applanation tonometer, is an accessory device installed into the 
optical axis of slit lamps. The Pascal DCT was mounted and aligned on a Haag Striet slit lamp 
(Picture2, Annexure IV).  Illumination on slit lamp was set to intermediate, using white light to 
allow easy viewing of the Sensor Tip /Cornea interface.  Sensor cap (sterile, disposable tip cover 
which is made especially for Pascal DCT) was fit to the Sensor Tip prior to the measurements 
(Picture 3, Annexure IV) and disposed after single use.  
All measurements were done by a standard technique under topical anesthesia. 2 values of OPA 
and IOP of quality factor 1 or 2 were measured on each occasion and their average value was 
taken for analysis. A drop of 0.5% Proparacaine, a topical anesthetic was instilled to the patient’s 
eye.  No fluorescein was used.  The patient was asked to blink a few times and then requested to 
keep the eye wide open and looking straight ahead. The examiner, looking from the side, aligned 
the end of the sensor tip close to the apex of the patient’s cornea.  
The Pascal unit was switched on by turning Blue Knob (Picture 3, Annexure IV) gently in clock 
wise direction by about 10 degrees until a click felt, and then the knob was released. The 
message “please wait” system test would appear on the LCD.  Upon completion of the internal 
self test, which takes approximately three seconds, the LCD would display a reminder message 
“Always use cap”. The LCD display would also read “OK.  Recording” (Picture 4, Annexure IV) 
indicates that the device was active and ready to record data.  Looking through left ocular, the 
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slit lamp is advanced until the surface of the sensor tip touched the cornea (Picture 5, Annexure 
IV).   
 The area where the sensor tip touched the patient’s cornea, contact zone would appear as darker 
area (Picture 6, Annexure IV) that is circular when the sensor tip was properly centered. Using 
the joystick on the slit lamp, the position of the sensor tip was adjusted until the opaque spot 
enclosing the blue green square of the pressure sensor was concentric with the contact zone 
(Picture 6, Annexure IV) Regular continuous oscillating sound is heard which is generated by the 
pulsating IOP when the sensor tip had established correct contact and alignment with the cornea. 
Approximately 5 to 7 consecutive beeps (indicating successive cardiac cycles) are necessary to 
obtain an undisturbed wave form.  After counting approximately five to seven wave forms of the 
oscillating sound the sensor tip was swiftly removed away from the patient’s eye.   
When pressure sensed by the Pascal drops to zero upon interruption of contact with cornea, the 
sound would vanish and a double beep would confirm that the zero pressure base line has been 
detected.  This decoupling of the sensor tip from the cornea will be referred to as performing an 
Interrupt maneuver.  The Pascal would now compute IOP and OPA from the pressure curve just 
recorded.  The LCD is illuminated for 20 seconds and the results (IOP, OPA and QF-quality 
factor) displayed for a total of 60 seconds (Picture 7, Annexure IV).  The results as well as the 
waveforms were directly transferred to the computer for data storage using appropriate software. 
The same procedure was restarted for the next measurements. Two measurements were taken for 
each patient. 
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Measurement of Blood Pressure: 
Blood pressure of each patient participating in the study was recorded using a 
sphygmomanometer. Right arm of the patient was selected for measurement of blood pressure 
with the patient in sitting position and with the flexed elbow at the level of the heart. The arm 
was exposed 5 inches above the elbow and any restrictive clothing was removed. The 
sphygmomanometer cuff of appropriate size was wrapped around the upper arm with the lower 
edge one inch above the antecubital fossa.  
First, the palpatory method of blood pressure recording was done. The radial pulse was found 
with the first 3 fingers. While palpating the radial pulse, the cuff was inflated 30 mmHg above 
the pressure at which the pulse disappears. The level of the pressure at which the pulse 
disappears and subsequently reappears on deflation was noted as the systolic pressure. 
Auscultatory method of blood pressure recording was done subsequently with the help of a 
stethoscope.  Stethoscope is placed over the brachial artery on the antecubital fossa and the cuff 
was inflated to a level above the systolic pressure recorded with palpatory method.  The cuff was 
gradually deflated and the pressure was noted at which the first Korotkoffs sound was heard and 
was recorded as the systolic pressure. The level of pressure at which the Korotkoffs sound 
disappears permanently was taken as the diastolic pressure.  
  
Measurement of Blood Sugar levels: 
Laboratory investigations like Fasting Plasma Glucose (FPG) and Serum Creatinine were 
checked for those patients in the exposed group and FPG alone was checked for the non exposed 
group.  Fasting plasma glucose was done in the lab according to American Diabetic association 
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guidelines 2013 (76). Patient was advised fasting, which is defined as no caloric intake for ≥ 8 
hours by ADA 2013 guidelines. Glucose orthotoluidine method was the test used to find out the 
FPG of each patient. Blood sample was taken in a test tube with grey cap containing sodium 
fluoride and the sample was centrifuged for 5 minutes. The centrifuged sample was kept in 
Roche Modular machine which gives the results after 20 minutes. Patients who had FPG ≤ 126 
mg/dl (ADA 2013 guidelines) were diagnosed as non diabetics and were included in the study.  
Serum creatinine was done in the lab using Jaffe’s method. Blood sample was collected in a test 
tube with red cap and was centrifuged for 10 minutes. The centrifuged sample was further kept 
in Roche Modular machine and the results read after 20 minutes.  
 
Sample size calculation:  
Given the non availability of literature on OPA in ESRD, we conducted a pilot study to help us 
calculate the sample size. The pilot study consisted of 8 patients each in exposed and non 
exposed group. Using DCT, we measured the OPA of all the patients. The measurements with 
quality factor 1 or 2 were taken and compared. When we compared the values that we obtained 
during the pilot study, we found that the OPA of patients with end stage renal disease (exposed 
group) were significantly lower than the normal individuals (non exposed group). The values that 
we obtained are as shown in the following table.  
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OPA in End stage renal disease patients OPA in normal individuals 
1.8 3.5 
0.8 2.8 
1.2 2.3 
0.8 3.5 
1.5 3.4 
1.3 3.1 
3.4 3.2 
2.9 3.1 
 
We used two mean hypotheses testing for obtaining the sample size and we got a sample size of 
44 in each arm using the following formula,   
    
 Where ‘n’ is the sample size, 
            ‘α’ is the error,  
            ‘1-β’ is the power,  
            ‘S’ is the standard error and 
             ‘d’ is the clinically meaningful difference between the 2 groups. 
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The sample size calculation was obtained as shown in the following table. 
Two mean 
hypothesis 
testing for 
two means 
     
SD in Group 1 2 2 2 2 3.5 
SD in Group 2 1 1 2 3 2.5 
Mean 
difference 
1.2 1.5 1.5 1.5 1.5 
Effect size 0.8 1 0.75 0.5 0.6 
Alpha error 5 5 5 5 5 
Power(1-
beta) % 
81 80 80 80 80 
1 or 2 sided 2 2 2 2 2 
Required 
sample size 
per group 
28 17 28 63 44 
  
Data entry was done in an excel sheet and analyzed using SPSS version 17. The OPA in both 
eyes were averaged separately for all 88 subjects (44 exposed and 44 non-exposed) and used for 
analysis using Mann Whitney U test. Student t test was also used to look at statistical 
significance on parameters such as OPA and IOP in the exposed and the non exposed groups. 
We also looked at correlation between OPA and parameters like age, gender, IOP and BP and 
serum creatinine levels in patients with ESRD, using Pearson’s correlation coefficient (r).  
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                  RESULTS AND ANALYSIS 
 
The data collected from 44 patients among the exposed and 44 patients among the non-exposed 
group were analyzed. Among the exposed group, 30 male patients and 14 female patients 
participated in the study (Graph 1) whereas among the non-exposed group, 13 male patients and 
31 female patients took part in the study (Graph 2). The averaged OPA in the right and left eyes 
of each patient was used separately for analysis. 
 
Graph 1: Male to female ratio in the exposed group: 
Male
68%
Female
32%
Gender distribution
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Graph 2: Male to female ratio in the non-exposed group: 
 
 
 
In the exposed group we had patients from 18 years to 67 years of age (Graph 3). Hence we 
recruited age matched individuals from 18 to 64 years (Graph 4) to form the non-exposed group. 
Among the exposed group, 16 patients were under the age group of 18-28 years, 13 patients were 
under the age group of 29-38 years, 9 patients were under the age group of 39-48 years, 3 
patients were under the age group of 49-58 and 3 patients were under the age group of 59-68 
years. Among the non-exposed group, 18 patients were under the age group of 18-28 years, 12 
patients were under the age group of 29-38 years, 9 patients were under the age group of 39-48 
years, 3 patients were under the age group of 49-58 years and 2 patients were under the age 
group of 59-68 years. 
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Graph 3: Age distribution among the exposed group: 
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Graph 4: Age distribution among the non- exposed: 
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Ocular Pulse Amplitude (OPA):  
OPA was measured for each eye separately. The means and standard deviations (SD) of the OPA 
for each eye was calculated for both the exposed and non exposed groups. The standard error 
was calculated using the formula SE = SD/n where n is the sample size. The 95% confidence 
interval was then calculated. 
Among the exposed group in the right eye, 4 patients had OPA < 1.0 mm Hg, 21 patients had 
OPA between 1.1-2.0 mm Hg, 17 patients had OPA between 2.1 to 3.0 and 2 patients had OPA 
between 3.1-4.0 mm Hg. The distribution of OPA among the exposed group is as shown below 
(Table 1). 
Table 1: OPA among the exposed group (right eye):  
OPA FREQUENCY PERCENTAGE 
0.0-1.0 4 9.09  
1.1-2.0 21 47.73  
2.1-3.0 17 38.64  
3.1-4.0 2 4.54 
 
 The mean OPA (RE) in the exposed group was 1.945  0.65 mm Hg. The standard error SE was 
calculated to be 0.098. Thus the OPA in the right eye in patients with ESRD was found to be 
1.945(CI: 1.847 - 2.043). The frequency distribution of OPA in the exposed group is given in the 
histogram below (Graph 5) 
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Graph 5: OPA in the exposed group (right eye): 
OPA among Exposed
0
5
10
15
20
25
0-1.0 1.05-2 2.1-3 >3
OPA
F
re
q
u
e
n
c
y
 
   OPA among the non-exposed (right eye) ranged from 1.0 to 3.25 mm Hg. Among the non-
exposed group, 1 patient had OPA between 0.0 to 1.0, 17 patients had OPA between 1.05-2.0 
mm Hg, 23 patients had OPA between 2.1-3.0 mm Hg and 3 patients had OPA between 3.1-4.0 
mm Hg. The distribution of OPA among the non-exposed group is as shown below (Table 2). 
Table 2: OPA among the non-exposed group (right eye): 
OPA FREQUENCY PERCENTAGE 
0.0-1.0 1 2.27  
1.05 -2 17 38.64  
2.1-3.0 23 52.27  
3.1-4.0 3 6.82  
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The mean OPA (RE) in the non exposed group was 2.16  0.58 mm Hg. The standard error SE 
was calculated to be 0.087. Thus the OPA in the right eye in normal subjects was found to be 
2.16(CI: 2.08-2.24). The frequency distribution is as shown in Graph 6. 
Graph 6: OPA in the non-exposed group (right eye): 
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Comparison of OPA among exposed and non-exposed group (right eye): 
The mean OPA in the exposed group and non-exposed group were 1.945(CI: 1.847 - 2.043) and 
2.16(CI: 2.08-2.24) respectively. The exposed group had lower OPA as compared to non- 
exposed group. There was a statistically significant difference between the 2 groups (p = 0.03). 
The confidence intervals do not overlap. Graph 7 shows the mean OPA in the right eye among 
exposed and non exposed subjects. 
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Graph 7: OPA among exposed and non-exposed: 
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Among the exposed group in the left eye, 4 patients had OPA 1.0 mm Hg, 18 patients had OPA 
between 1.1-2.0 mm Hg, 16 patients had OPA between 2.1 to 3.0and  6 patients had OPA 
between 3.1-4.0 mm Hg The distribution of OPA among the exposed group is as shown below 
(Table 3). 
Table 3: OPA among the exposed group (left eye):  
OPA FREQUENCY PERCENTAGE 
0.0-1.0 4 9.09  
1.1-2.0 18 47.73  
2.1-3.0 16 38.64  
3.1-4.0 6 4.54 
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The mean OPA (LE) in the exposed group was 2.10 0.80 mm Hg. The standard error SE was 
calculated to be 0.12. Thus the OPA in the left eye in patients with ESRD was found to be 
2.10(CI: 1.98 - 2.22). The frequency distribution of OPA in the exposed group is given in the 
histogram below (Graph 5) 
 
Graph 8: OPA in the exposed group (left eye): 
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   OPA among the non-exposed (left eye) ranged from 1.0 to 3.25 mm Hg. Among the non-
exposed group, 12 patients had OPA between 1.05-2.0 mm Hg, 27 patients had OPA between 
2.1-3.0 mm Hg and 5patients had OPA between 3.1-4.0 mm Hg. The distribution of OPA among 
the non-exposed group is as shown below (Table 4). 
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Table 4: OPA among the non-exposed group (left eye): 
OPA FREQUENCY PERCENTAGE 
0.0-1.0 0 0  
1.05 -2 12 27.27  
2.1-3.0 27 61.36  
3.1-4.0 5 11.37  
 
The mean OPA (LE) in the non exposed group was 2.35  0.53 mm Hg. The standard error SE 
was calculated to be 0.07. Thus the OPA in the right eye in normal subjects was found to be 
2.35(CI: 2.28-2.42). The frequency distribution is as shown in Graph 6. 
 
Graph 9: OPA in the non-exposed group (left eye): 
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Comparison of OPA among exposed and non-exposed group (left): 
The mean OPA in the exposed group and non exposed group were 2.10(CI: 1.98 - 2.22) and 
2.35(CI: 2.28-2.42) respectively. The exposed group had lower OPA as compared to non 
exposed group. There was a statistically significant difference between the 2 groups (p = 0.02). 
The confidence intervals do not overlap. Graph 7 shows the mean OPA in the right eye among 
exposed and non exposed subjects. 
 
Graph 10: OPA among exposed and non – exposed: 
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1.95
2
2.05
2.1
2.15
2.2
2.25
2.3
2.35
2.4
Exposed Non exposed
O
P
A
 
 
 
 
53 
 
There was a strong  positive correlation between OPA in right and left eye (r=0.79) among the 
exposed group. 
Graph 11: Correlation between OPA in the right eye and left eyes among exposed: 
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There was only a moderate correlation between OPA in the right and left eyes among the non-
exposed (r=0.32). 
Graph 12: Correlation between OPA in the right and left eyes among non – exposed: 
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Table 5: Comparison of IOP in the right eye among exposed and non-exposed group: 
 EXPOSED NON-EXPOSED p VALUE 
 MEAN SD MEAN SD  
0.083 IOP (right eye)  16.53 2.43 17.31 2.80 
 
Graph 13: Bar diagram showing comparison of IOP in the right eye among exposed and non-
exposed group: 
 
 
IOP in the right eye among exposed was slightly lower than the non-exposed group but was not 
statistically significant. The IOP in the left eye also showed a similar trend. 
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Table 6: Comparison of IOP in the left eye among exposed and non-exposed group:  
 EXPOSED NON-EXPOSED p VALUE 
 MEAN SD MEAN SD  
0.579 IOP(Left eye) 16.39 2.44 16.64 3.17 
 
The median age of subjects in the exposed and non exposed groups was 30. Hence we looked at 
OPA in those patients who were ≤ 30 years and those who were > 30 years. 
Table 7: Comparison of OPA in the right eye in age ≤ 30 years among exposed and non-exposed 
group: 
AGE ≤ 30 EXPOSED NON-EXPOSED p VALUE 
 MEAN SD MEAN SD  
0.70 OPA (Right eye) 
 
1.70 0.61 1.78 0.66 
 
OPA in the right eye in the age group ≤ 30 years (n=21) was slightly lower in exposed group 
compared to non-exposed group and it was not statistically significant. 
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Table 8: Comparison of IOP (right eye) of age ≤ 30 years among exposed and non-exposed 
group: 
AGE ≤ 30 EXPOSED NON-EXPOSED p VALUE 
 MEAN SD MEAN SD  
0.03 IOP (Right eye) 16.17 1.99 18.34 2.19 
 
RE IOP in age group ≤ 30 years was lower in the exposed group compared to the non-exposed 
group and it was statistically significant. 
Graph 14: Bar diagram showing comparison of RE IOP in age ≤ 30 years: 
RE IOP in age ≤ 30 years
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IOP in the right eye in age group < 30 years was lower in the exposed group compared to the 
non-exposed group and it was statistically significant. 
 
Table 9: Comparison of IOP (left eye) in age ≤ 30 years among exposed and non-exposed group: 
 
AGE ≤ 30 EXPOSED NON-EXPOSED p VALUE 
 MEAN SD MEAN SD  
0.228 IOP(Left eye) 16.27 1.92 17.33 2.86 
 
IOP in the left eye in the age group < 30 years was lower in the exposed group compared to the 
non-exposed group and it was not statistically significant. 
Graph 15: Bar diagram showing comparison of IOP (left eye) in age ≤ 30 years: 
LE IOP in age ≤ 30 years 
12
14
16
18
20
Exposed Non-exposed
 
58 
 
 
 
 
 
 
Table 10: Comparison of OPA (right eye) in patients with age > 30 years among exposed and 
non-exposed group: 
 
AGE > 30 EXPOSED NON-EXPOSED p VALUE 
 MEAN SD MEAN SD  
0.288 OPA (right eye) 2.41 0.89 2.69 0.88 
 
OPA in the right eye in patients with age > 30 years of age was lower among the exposed 
compared to non-exposed group, but it was not statistically significant. 
 
Table 11: Comparison of IOP (right eye) in age > 30 years among exposed and non-exposed 
group: 
AGE > 30 EXPOSED NON-EXPOSED  p VALUE 
 
 
MEAN SD MEAN SD  
0.934 
IOP (right eye) 16.86 2.78 16.53 3.00 
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Graph 16: Bar diagram showing comparison of IOP (right eye) in age > 30 years: 
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IOP in the right eye in the age group > 30 years was higher in the exposed group compared to the 
non-exposed group, and it was not statistically significant. 
Table 12: Comparison of IOP (left eye) in age > 30 years among exposed and non-exposed 
group: 
 
AGE > 30 EXPOSED NON-EXPOSED  p VALUE 
 MEAN SD MEAN SD  
0.773 IOP(left eye) 16.50 2.84 16.12 3.27 
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Graph 17: Bar diagram showing comparison of LE IOP in age > 30 years: 
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IOP in the left eye in the age group > 30 years was higher in the exposed group compared to the 
non-exposed group, and it was not statistically significant. 
 
Table 13: Comparison of OPA (both eyes) in females among exposed and non-exposed group: 
FEMALES EXPOSED NON-EXPOSED p VALUE 
 MEAN SD MEAN SD  
0.008 OPA (both eyes) 1.82 0.88 2.54 0.81 
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Graph 18: Bar diagram showing comparison of BE OPA in females: 
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OPA in both eyes in female patients was lower among the exposed compared to non-exposed 
group and it was not statistically significant. 
 
Table 14: Comparison of OPA (both eyes) in males among exposed and non-exposed group: 
MALES EXPOSED NON-EXPOSED p VALUE 
 MEAN SD MEAN SD  
0.182 OPA (both eyes) 2.29 0.93 2.62 0.77 
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Graph 19: Bar diagram showing comparison of BE OPA in males: 
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OPA in both eyes in male patients was lower among the exposed compared to non-exposed 
group but was not statistically significant. 
 
Table 15: Comparison of IOP (right eye) in females among exposed and non-exposed group: 
FEMALES EXPOSED NON-EXPOSED  p VALUE 
 MEAN SD MEAN SD  
0.548  IOP (right eye) 16.88 2.19 16.90 2.58 
 
IOP in the right eye in females was lower in the exposed group compared to the non-exposed 
group, but it was not statistically significant. 
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Graph 20: Bar diagram showing comparison of RE IOP in females: 
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Table 16: Comparison of IOP (left eye) in females among exposed and non-exposed group: 
 
FEMALES EXPOSED NON-EXPOSED  p VALUE 
 MEAN SD MEAN SD  
0.677 IOP(left eye) 16.24 1.84 16.15 3.02 
 
IOP in the left eye in females was higher in the exposed group compared to the non-exposed 
group, and it was not statistically significant. 
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Graph 21: Bar diagram showing comparison of IOP (left eye) in females: 
LE IOP in females
12
14
16
18
Exposed Non-exposed
 
 
 
 
 
Table 17: Comparison of IOP (right eye) in males among exposed and non-exposed group: 
 
MALES EXPOSED NON-EXPOSED  p VALUE 
 MEAN SD MEAN SD  
  0.062 IOP(right eye) 16.37 2.55 18.29 3.16 
  
IOP in the right eye in males was lower in the exposed group compared to the non-exposed 
group, but it was not statistically significant. 
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Graph 22: Bar diagram showing comparison of RE IOP in males: 
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Table 18: Comparison of IOP (left eye) in males among exposed and non-exposed group: 
 
MALES EXPOSED NON-EXPOSED  p VALUE 
 MEAN SD MEAN SD  
0.255 IOP (left eye) 16.46 2.63 17.83 3.11 
 
IOP in the left eye in males was lower in the exposed group compared to the non-exposed group, 
but it was not statistically significant. 
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Graph 23: Bar diagram showing comparison of IOP (right eye) among exposed and non-exposed 
group: 
LE IOP in males
12
14
16
18
20
Exposed Non-exposed
 
 
 
 
Table 19: Comparison of OPA (both eyes) among exposed and non-exposed group with systolic 
BP ≤ 120 mm Hg: 
 
SYSTOLIC BP ≤ 
120 
EXPOSED NON-EXPOSED  p VALUE 
 MEAN SD MEAN SD  
0.012 OPA( both eyes) 2.15 0.93 2.57 0.78 
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OPA in both eyes among exposed group with Systolic BP ≤ 120 mm Hg was lower than those 
among the non-exposed group and it was statistically significant.  
Graph 24: Bar diagram showing comparison of OPA (both eyes) with BP ≤ 120 mm Hg: 
BE OPA in Systolic BP ≤ 120 mm Hg
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Table 20: Comparison of IOP (right eye) among exposed and non-exposed group with systolic 
BP ≤ 120 mm Hg: 
 
SYSTOLIC BP ≤ 120 EXPOSED NON-EXPOSED  p VALUE 
 MEAN SD MEAN SD  
0.177 IOP (right eye) 15.79 1.73 17.47 3.09 
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IOP in the right eye among exposed group with systolic BP ≤ 120 mm Hg was lower than those 
among the non-exposed group, but it was not statistically significant.  
Graph 25: Bar diagram showing comparison of IOP (right eye) with BP ≤ 120 mm Hg: 
RE IOP in Systolic BP ≤ 120 mm Hg
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IOP in the left eye among exposed group with Systolic BP ≤ 120 mm Hg was lower than those 
among the non-exposed group, but it was not statistically significant.  
 
Table 21: Comparison of IOP (left eye) among exposed and non-exposed group with systolic BP 
≤ 120 mm Hg: 
SYSTOLIC 
BP ≤ 120 
EXPOSED NON-EXPOSED  p VALUE 
 MEAN SD MEAN SD  
0.198 IOP( left eye) 15.13 1.83 16.76 3.48 
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Graph 26: Bar diagram showing comparison of IOP (left eye) with BP ≤ 120 mm Hg: 
LE IOP in Systolic BP ≤ 120 mm Hg
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We could not compare OPA or IOP among exposed and non-exposed with systolic BP > 120 
mm Hg as non-exposed group comprised of those with systolic BP ≤ 120 mm Hg. 
 
 
Table 22: Comparison of OPA (both eyes) among exposed and non-exposed group with diastolic 
BP ≤ 80 mm Hg: 
 
DIASTOLIC 
BP ≤ 80 
EXPOSED NON-EXPOSED  PVALUE 
 MEAN SD MEAN SD  
0.012 OPA(both eyes) 1.57 0.63 2.69 0.94 
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OPA in both eyes among exposed group with diastolic BP ≤ 80 mm Hg was lower than those 
among the non-exposed group and it was statistically significant.  
Graph 27: Bar diagram showing comparison of OPA (both eyes) with BP ≤ 80 mm Hg: 
BE OPA in Systolic BP ≤ 80 mm Hg
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Table 23: Comparison of IOP (right eye) among exposed and non-exposed group with diastolic 
BP ≤ 80 mm Hg: 
 
DIASTOLIC 
BP ≤ 80 
EXPOSED NON-EXPOSED  p VALUE 
 MEAN SD MEAN SD  
0.097 IOP (right 
eye) 
15.45 1.68 17.30 2.90 
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RE IOP among exposed group with Systolic BP ≤ 80 mm Hg was lower than those among the 
non-exposed group, but it was not statistically significant.  
 
Graph 28: Bar diagram showing comparison of IOP (right eye) with BP ≤ 80 mm Hg: 
RE IOP in Systolic BP ≤ 80 mm Hg
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Table 24: Comparison of IOP (left eye) among exposed and non-exposed group with diastolic BP 
≤ 80 mm Hg: 
 
DIASTOLIC 
BP ≤ 80 
EXPOSED NON-EXPOSED  p VALUE 
 MEAN SD MEAN SD  
0.097 IOP (left eye) 14.51 2.10 16.51 3.29 
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IOP in the left eye among exposed group with Systolic BP ≤ 80 mm Hg was lower than those 
among the non-exposed group, but it was not statistically significant.  
 
Graph 29: Bar diagram showing comparison of IOP (LE) with BP ≤ 80 mm Hg: 
LE IOP in Systolic BP ≤ 80 mm Hg
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We could not compare OPA or IOP among exposed and non-exposed with diastolic BP > 80 mm 
Hg as non-exposed group comprised of those with diastolic BP ≤ 80 mm Hg. 
 
We compared IOP and OPA among exposed and non-exposed individuals and we found that 
there was no correlation between IOP and OPA in either group. 
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Graph 30: Correlation between IOP and OPA among exposed subjects in right eye: 
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There was no correlation between IOP and OPA in the right eye among the non-exposed 
(r=0.16). 
Graph 31: Correlation between IOP and OPA among exposed subjects in left eye: 
Correlation between IOP and OPA in the exposed group (left 
eye)
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There was no correlation between IOP and OPA in the left eye among the non-exposed (r=0.17). 
 
 
Graph 32: Correlation between IOP and OPA among non exposed subjects in the right eye: 
Correlation between IOP and OPA among non exposed 
(right eye)
0
5
10
15
20
25
0 0.5 1 1.5 2 2.5 3 3.5 4
OPA
IO
P
 
 
No correlation existed between IOP and OPA in the right eye among the non-exposed (r=0.109). 
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Graph 33: Correlation between IOP and OPA among  non exposed subjects in left eye: 
Correlation between IOPand OPA among non exposed (left 
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Between IOP and OPA in the left eye among the non-exposed also there was no correlation. 
(r=0.206). 
 
We compared OPA and IOP with Serum creatinine levels in both eyes in the exposed and non-
exposed group, but there was no correlation in any of the group. 
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Graph 34: Correlation between OPA and Serum creatinine among exposed subjects in right eye: 
Correlation between OPA and Serum creatinine levels 
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There was no correlation between OPA in the right eye and serum creatinine among the exposed 
(r=0.049). 
Graph 35: Correlation between OPA and Serum creatinine among exposed subjects in left eye: 
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There was no correlation between OPA in the left eye and serum creatinine among the non-
exposed (r = -0.0065). 
 
 
Graph 36: Correlation between IOP and Serum creatinine among exposed subjects in right eye: 
Correlation between IOP and serum creatinine 
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There was no correlation between IOP in the right eye and serum creatinine among the non-
exposed (r = -0.055). 
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Graph 37: Correlation between IOP and Serum creatinine among exposed subjects in left eye: 
Correlation between IOP and serum creatinine 
levels among exposed (left eye)
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There was no correlation between IOP in the left eye and serum creatinine among the non-
exposed (r = -0.153). 
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                                                    DISCUSSION 
 
 Patients with end stage renal disease (ESRD) who are on hemodialysis are always at a risk of 
developing eye diseases.  Choroidopathy is a main complication that occurs in these patients and 
the only method to study the severity of the disorders of the choroid is Indocyanine Green 
angiography (ICGA).Given the invasive nature of ICGA, it is life threatening and hence 
contraindicated in ESRD (51). Moreover to look for improvement in choroidal perfusion after 
renal transplant surgery, using this invasive procedure may not be advisable since ICG may be 
toxic to the donor kidney. 
OPA is the fluctuation of IOP with heart rate and it is an indirect indicator of the choroidal 
perfusion. OPA can be measured with the help of Dynamic Contour Tonometer (DCT) which 
helps in the simultaneous recording of OPA and IOP. According to literature, normal OPA 
ranges from 1-3.4 mm Hg and there was positive correlation between OPA and IOP (36). 
Significant asymmetry of OPA has been documented in patients with vascular stenosis (15, 16) 
and arteriovenous fistulas and there was a significant increase in pulsatile ocular blood flow in 
those patients with moderate to severe NPDR (8, 9). Studies on diabetic retinopathy and ocular 
pulse amplitude have shown varying results. Hypertension and end stage renal diseases are 
associated with choroidopathy (20-21). However, no correlation between OPA and systemic or 
diastolic blood pressures or their amplitudes is reported in available literature (6).  
We looked at OPA as a surrogate for ICGA to look at choroidal perfusion in patients with ESRD 
on hemodialysis and compared them with age matched normals. Till date there are no studies 
which have measured OPA in end stage renal disease. Hence we did a pilot study to see if there 
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is any difference in OPA between patients with ESRD and normals, which indicated that the 
OPA in patients with ESRD was significantly lower than normal individuals.  We chose patients 
with ESRD with no diabetes to ensure that OPA is not affected by diabetes and retinopathy if 
any. Since the patients were undergoing hemodialysis their blood pressures were also normal. 
Analyzing the OPA in the right and left eyes separately would ensure that measurement errors 
and biases are eliminated. 2 values of OPA with quality factor 2 or less also minimized errors in 
measurement. In both right and left eyes the OPA in patients with ESRD was statistically 
significantly lower than age matched normals. In the right eye the mean OPA was 1.945mm Hg 
(CI: 1.847 - 2.043) and 2.16mm Hg (CI: 2.08-2.24) in the ESRD group and normals respectively. 
There was a statistically significant difference between the 2 groups (p = 0.03). The fact that the 
confidence intervals do not overlap clearly indicates that there is a difference between the 2 
groups. The mean OPA in the exposed group and non exposed groups in the left eye were also 
statistically significantly different (p = 0.02).  
Similar to the study by Purjavan et al., (36) there was a very strong positive correlation 
(Pearson’s correlation coefficient r= 0.79) between OPA in the right and left eyes in patients with 
ESRD thus showing that both eyes have similar OPA (p=0.03). Similar correlation existed 
between IOP (r=0.74) in both eyes in patients with ESRD.  
Studies by Kaufmann et al., (2) Stalmans et al., (27) and Purjavan et al., (36) found positive 
correlation between OPA and IOP as measured using DCT in normal subjects. However in our 
study we found no correlation between OPA and IOP using DCT in patients with ESRD as well 
as normal subjects.  
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With the assumption that age related changes in the choroidal blood flow can affect the OPA we 
divided the patients into those who were 30 years or less and those more than 30 years. 30 years 
being the median age, was chosen as the cut off. The reason for this assessment was to see if 
ESRD related choroidal changes not affected by age will show a greater difference in OPA 
compared to normals. With age considered as a confounding factor we assumed a considerable 
difference in OPA between exposed and non exposed patients in the younger subset of patients, 
which would compensate even when our sample size was halved.  Age however, did not seem to 
account for changes in OPA in patients with ESRD. Thus aging and related choroidal changes do 
not seem to affect the ocular pulse amplitude as measured using DCT though one needs to look 
at this finding critically after increasing the sample size.  
From our study it is reasonably clear that ocular pulse amplitude is statistically significantly 
lower in patients with end stage renal disease suggesting significant choroidopathy in these 
patients.  The patients recruited for our study were those undergoing hemodialysis and hence had 
normal blood pressure at the time of measuring OPA. Therefore the influence of high blood 
pressure on OPA could not be studied. The OPA would probably have been lower if we had 
recruited patients who were not on dialysis or if these measurements were taken just before the 
dialysis and compared with the values of the OPA after dialysis. This probably would have given 
us a better insight into the ocular blood flow in these patients. However, this was not within the 
scope of our study. 
In this study we postulate that measurement of OPA can be used as an alternative, simple 
noninvasive test to assess the choroidal perfusion in patients with end stage renal disease. In 
patients with ESRD on dialysis we found decreased OPA indicating decreased choroidal 
perfusion in ESRD. Following up and measuring the OPA in patients with ESRD prior to 
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dialysis, immediately after dialysis and after renal transplantation would help us understand the 
changes in OPA and choroidal perfusion with treatment. This knowledge may also help us use 
OPA as a tool to detect the success of renal transplantation as it could potentially improve 
choroidal perfusion.  
In addition, subsequent studies on subjects with early nephropathy may give us a clue as to 
whether OPA measurement can be used for early detection of nephropathy which can go 
undetected especially in those with no hypertensive retinopathy. 
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                                 LIMITATIONS 
 
1. All patients had normal blood pressure at the time of measuring OPA. We could have 
recruited another set of 44 patients with hypertension but no renal disease. 
2. Measuring OPA in patients before and after dialysis would have given a true picture of 
the influence if any of dialysis on the OPA. 
3. Doubling the sample size would have been helpful in detecting the effect of age on 
measured OPA.  
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                                                  CONCLUSIONS  
 
 The mean OPA in non diabetic patients with end stage kidney disease was 
1.945mm Hg (CI: 1.847 - 2.043).  
 The mean OPA in age matched normals was 2.16mm Hg (CI: 2.08-2.24) 
 The OPA in non diabetic patients with end stage renal disease was statistically 
significantly lower than that of age matched normals (p=0.03). 
 There was no correlation between OPA and other parameters age, gender or 
intraocular pressure. 
 There was no correlation between OPA and blood pressure or  serum creatinine 
levels 
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                                                                            APPENDIX I 
                                                         CLINICAL PROFORMA 
 
 
 
Study no  
Exposed  / non exposed group  
Date of Enrollment  
Name  
Age  
Schell Eye Hospital No  
CMC Hospital No  
Address  
Contact No  
Date of Examination  
Blood Pressure  
AC  
Creatinine  
DCT – Recording RE OPA RE IOP LE OPA LE IOP 
DCT – 1st reading     
DCT – QF (1st reading)   
DCT – 2nd reading     
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                                        APPENDIX II 
                               PATIENT INFORMATION SHEET IN ENGLISH 
 
                                              Christian Medical College, Vellore 
                                                Department of Ophthalmology 
 
Ocular Pulse Amplitude in non Diabetic patients with end stage renal disease on dialysis and normal 
individuals using Dynamic Contour Tonometry-A Cross sectional Study 
 
                                                         Patient Information sheet 
 
You are being requested to participate in a study to see the difference in measurement of 
Ocular Pulse Amplitude (OPA) in patients with renal disease on dialysis and normal individuals 
with an instrument called Dynamic Contour Tonometer (DCT). This instrument is used to 
measure the intraocular pressure (IOP) which is important in the diagnosis of a blinding disease 
called glaucoma. Along with measuring IOP, DCT also measures OPA. We hope to include about 
88 patients (44 with kidney disease and 44 with no kidney disease) from this hospital for this 
study. 
What are OPA and DCT? 
  OPA is an indirect indicator of the blood supply to the eye especially the choroidal blood 
vessels, which helps in the nutrition of the retina. The retina is the light sensitive part of the 
eye. Choroidal perfusion is decreased in patients with kidney disease. Indocyanine Green 
Angiography has been used to look at choroidal perfusion in these patients earlier. But this is an 
invasive procedure, which requires injecting a dye in to the body and taking pictures of the eye. 
This dye is toxic to the kidneys and is definitely not preferred in patients who have kidney 
disease. Measurement of OPA using DCT is a non-invasive procedure which only requires a 
topical anesthetic to be instilled in the eye. 
Does the test have any side effects? 
No. There are no significant side effects for this test. 
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If you take part what will you have to do? 
If you agree to participate in this study, you have to come for a complete ophthalmic 
examination including OPA measurement using DCT. This will be like any routine eye 
examination and does not take any extra time. 
Can you withdraw from this study after it starts? 
Your participation in this study is voluntary. Not giving consent for participation in the study will 
not affect your treatment in this hospital. 
What will happen if you develop any study related injury? 
This procedure is not likely to have any ocular injuries. 
Will you have to pay for the test?  
No payment is required for the tests done for the study. 
What happens after the study is over? 
After the study is over the results of the study will be published in scientific journals. The names 
or identity of any of the participants will not be published. The hospital records will be kept in 
the Dept of Ophthalmology. Interested patients can be briefed about the results of the study. 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be identified by 
name in any publication or presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your additional permission, should you 
decide to participate in this study. 
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                                               CONSENT FORM IN ENGLISH 
                                      
                                     CONSENT TO TAKE PART IN A CLINICAL TRIAL 
 
 Study Title: Ocular Pulse Amplitude in non Diabetic patients with end stage renal disease on 
dialysis and normal individuals using Dynamic Contour Tonometry-A Cross sectional Study 
 
Study Number: 
 
Participant’s name:  
 
Hospital no: 
 
Date of Birth / Age (in years): 
 
I_____________________________________________________________, 
 
  Son/daughter of ___________________________________ 
 
(Please tick boxes) 
 
 Declare that I have read the information sheet provide to me regarding this study and 
have clarified any doubts that I had. [ ] 
 I also understand that my participation in this study is entirely voluntary and that I am 
free to withdraw permission to continue to participate at any time without affecting my 
usual treatment or my legal rights [ ] 
 I also understand that the test will be done free of cost [ ] 
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 I understand that the study staff and institutional ethics committee members will not 
need my permission to look at my health records even if I withdraw from the trial. I 
agree to this access [ ]                                                                                                                                                              
 I understand that my identity will not be revealed in any information released to third 
parties or when the results are published [ ]   
 I voluntarily agree to take part in this study [ ] 
 
Name: 
 
Signature/Thumb impression: 
 
Date: 
 
Name of witness: 
 
Relation to participant: 
 
Date:                           
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                         PATIENT INFORMATION SHEET IN TAMIL 
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                                   CONSENT FORM IN TAMIL 
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                                  PATIENT INFORMATION SHEET IN HINDI  
 
                ,       
                                                                                     
 
                                 औ            Tonometry ए  क्रॉस अनभुागीय       
                                             
 
 
                                                                                    
 
   ए                  ए          औ  ए                       (      )          
                                                           (OPA)                 
  ए                   . इ      ण     ए intraocular      (IOP)   ए                      
                   ण               ए                 . IOP            ,          OPA 
    .    इ                  88 (44 औ                                       44) इ  
          ए                            . 
OPA औ                    ? 
  OPA       ए                ए          choroidal                         ण      
         ए            .                                     .                    
                                      . Indocyanine     ए         इ              choroidal 
                  ए इ                .        ए               ,        ए      
इ     औ                          .                          औ                  
                            . OPA                        ए    इ                     
ए                               औ               . 
       ण                  ? 
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    इ     ण     ए         ण  इ  इ           . 
               ए               ? 
      इ                  ए       ,      ए    ण   OPA                         
         ए         .                        ण                औ               
       . 
   इ                                 ? 
इ                             .                 ए             ए इ         
    इ                    . 
                                           ? 
                                     . 
        ण     ए              ? 
                    ए            ण     ए        . 
                                  ? 
                   ण                                  ए  .                    
                              ए  .                                   ए  . इ    
                 ण                          . 
                                 ए  ? 
इ            ण      ए                        ए  ,                        
      ण                         ए  .       ,                                
                                     ,   इ                        
    ए. 
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                                                  CONSENT FORM IN HINDI 
 
एक चिककत्सीय परीक्षण में भाग लेने के के ललए सहमति 
 
 अध्ययन शीर्षक: अिं मिं वकृ्क रोग के साथ सामान्य डायलललसस और गतिशील कंटूर Tonometry एक  
क्रॉस अनभुागीय अध्ययन का उपयोग व्यक्तक्ियं पर गरै मधुमेह रोचगयं में नेत्र स्पदं आयाम 
 
अध्ययन सखं्या: 
 
प्रतिभागी का नाम: 
 
कोई अस्पिाल: 
 
जन्म / Age की िारीख (वर्ों में): 
 
I_____________________________________________________________, 
 
  बेटे की बेटी / ___________________________________ 
 
(कृपया टटक बक्स)े 
 
• घोर्णा की कक मैंने पढा है मझु ेइस अध्ययन के बारे में जानकारी पत्रक प्रदान करने और ककसी भी 
सदेंह है कक मैं था स्पष्ट है. [] 
• मैं भी समझि ेहैं कक इस अध्ययन में मेरी भागीदारी परूी िरह स्वकै्तछिक है और मझुे मेरे सामान्य 
उपिार या अपने काननूी अचधकारं को प्रभाववि ककए बबना करने के ललए ककसी भी समय में भाग लेने 
के ललए जारी करने की अनमुति को वापस लेने के ललए स्वितं्र है कक [] 
• मैं भी समझि ेहैं कक परीक्षण की लागि से मकु्ि [] ककया जाएगा 
• मैं इस बाि को समझिा हूूँ कक अध्ययन कमषिाररयं और ससं्थागि नतैिकिा सलमति के सदस्यं को 
मेरी अनमुति की जरूरि नहीं है मेरे स्वास््य ररकॉडष को देखन ेभी अगर मैं परीक्षण स ेहट जाएगा. मैं 
इस का उपयोग करने के ललए सहमि [] 
मैं समझिा हूूँ कक मेरी पहिान ककसी भी िीसरे पक्ष के ललए जारी सिूना में या पररणाम प्रकालशि कर 
रहे हैं जब खुलासा नहीं ककया जाएगा [] 
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• मैं स्वेछिा स ेइस अध्ययन में भाग लेने के] [करने के ललए सहमि 
 
नाम: 
 
हस्िाक्षर/          : 
 
तिचथ: 
 
गवाह का नाम: 
 
भागीदार के सबंधं: 
 
िारीख 
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                          PATIENT INFORMATION SHEET IN BENGALI 
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                                                CONSENT FORM IN BENGALI 
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                       PATIENT INFORMATION SHEET IN TELUGU 
 
తెలుపబడ్డ  
 
 
 
                                                  క్రిస్టి యన్ మడెికల్ క్ాలేజ్, వెలలూ రు 
                                                               నేత్ర వెైద్య శాఖ 
 
డ్యాలస్టస్ మరయిు డెైనమిక్ సమోననత్ కనననగుడ్్డులోని ఒతి్తడి నిరణ యించనట-A క్ాి స్ స్కె్షనల్ అధ్య నిం 
ఉపయోగిించి సాధారణ వ్యకుి లపెై చివ్ర ిద్శలోని మూత్రపటిండ్ వాయధి క్ాని మధ్నమేహ రోగులు సింబింధతి్ పల్్ 
ఆమిలిటయయడ్ 
 
 
                                                             రోగి సమాచార షటీ్ 
 
మీరు డ్యాలిస్టస్ మరియు డెైనమిక్ సమోననత్ కనననగుడ్్డ  లోపలి ఒతి్తడిని క్ొలిచే సాధ్నిం (DCT) అని ఒక పరకిరిం 
సాధారణ వ్యకుి లపెై మూత్రపటిండ్ వాయధి ఉనన రోగులలో సింబింధిత్ పల్్ ఆమిలటియయడ్ (OPA) యొకక క్ొలత్ తడేా 
చూడ్టానిక్ర ఒక అధ్య నింలో పాలగొ నేింద్నకు అభ్యరిథ ించిన చసేని నానరు. ఈ పరికరిం గాూ క్ోమా అనే బ ్ూ ిండిింగ్ వాయధి 
నిరాా రణలో ముఖయమెైన ఇద ికింటిలోని ఒతి్తడి (IOP) క్ొలిచేింద్నకు ఉపయోగిసాి రు. IOP క్ొలిచే పాటు, DCT కలడా OPA 
క్ొలుసని ింది. మమేు ఈ అధ్య నిం క్ోసిం ఈ ఆసనపత్తర ననిండి 88 రోగులకు (ఏ మూత్రపటిండ్ వాయధి మూత్రపటిండ్ వాయధి 44 
మరియు 44) ఉనానయ ఆశిసని నానము. 
OPA మరియు DCT ఏమిట?ి 
  OPA కననన రకి సరఫరా రెటనీా పౌషటి క్ాహార సహాయిం చేసని నన ముఖయింగా choroidal రకినాాలలు, ఒక పరోక్ష సూచిక. 
రెటనీా కింటి క్ాింత్త సననినత్మెైన భాగిం. Choroidal పింపటణీ మూత్రపటిండ్ వాయధి ఉనన రోగులలో క్షీణసిని ింది. గరిన్ 
ఆింజియోగిఫట Indocyanine ముింద్న ఈ రోగులలో choroidal పింపటణీ కు ఉపయోగిసాి రు. క్ానీ ఈ శరర ిం ఒక డెై సూది 
మరియు కింటి చితరా లు తీయడ్ిం అవ్సరిం ఒక గాటు పరక్రియ ఉింది. ఈ రింగు మూత్రపటిండాలు హానికరము మరియు 
ఖచిిత్ింగా మూత్రపటిండ్ వాయధి కలిగిన రోగులకు ప రా ధానయత్ లేద్న. DCT ఉపయోగిించి OPA యొకక క్ొలత్ మాత్రమే 
కననన నాటబడాడ య ఒక సమయోచిత్ మత్తి  అవ్సరమెైన క్ాని హానికర పరక్రియ. 
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పరరక్ష ఏ పరభావాలనన కలిగి ఉిందా? 
నిం ఈ పరరక్ష క్ోసిం ఎటువ్ింటి పరభావాలు కలడా ఉనానయ. 
మీరు పాలగొ నడానిక్ర ఉింట ేమీరు ఏమి ఉింటుింది? 
మీరు ఈ అధ్య నింలో పాలగొ నేింద్నకు మీరు అింగరకరసిని నానరు, మీరు DCT ఉపయోగిించి OPA క్ొలత్ సహా ఒక పూరిి 
కింటి పరరక్ష క్ోసిం చయేగలగాలి. ఈ ఏ రొటనీ్ కింటి పరరక్ష వ్ింటి ఉింటుింద ిమరయిు ఏ అద్నపు సమయిం తీసనక్ోద్న. 
ఇది మొద్లవ్ుత్తింది త్రాాత్ మీరు ఈ అధ్య నిం ననిండి వనెక్రక తీసనక్ోవ్చని? 
ఈ అధ్య నింలో మీ భాగసాామయిం నిరాహ ించబడ్్త్తింద.ి అధ్య నింలో భాగసాామయిం క్ోసిం అననమత్త ఇవ్ాడ్ిం లేద్న 
ఈ ఆసనపత్తరలో చిక్రత్్ మీ పరభావిత్ిం చేయద్న. 
మీరు ఏ అధ్య నిం సింబింధతి్ గాయిం అభివ్ృదిా  చసే్తి  ఏమవ్ుత్తింది? 
ఈ పరక్రియ ఏదెైనా కింటి గాయాలు అవ్క్ాశిం లేద్న. 
మీరు పరరక్ష క్ోసిం చెలిూ ించవ్లస్ట ఉింటుింది? 
సింఖయ చెలిూ ింపు అధ్య నిం చసే్టన పరరక్షలు అవ్సరిం. 
అధ్య నిం పూరియాయక ఏమి జరుగుత్తింది? 
అధ్య నిం అధ్య న ఫలితాలు ముగిస్టన త్రాాత్ శాస్ీి యీ పత్తరకలు పరచనరిించబడ్్త్తింది. పాలగొ నవేారు ఏ పతరుూ  లేదా 
గురిి ింపు పరచనరతి్మెైన క్ాద్న. ఆసనపత్తర రకి్ారుడ లు నతే్ర వెైద్య Dept లో ఉించబడ్్త్తింది. ఆసక్రి అధ్య న ఫలితాలు 
ముటిి డపిెై చేయవ్చని. 
మీ వ్యక్రి గత్ వివ్రాలు గోపయింగా ఉించబడ్్త్తింది? 
ఈ అధ్య నిం యొకక ఫలితాలు మెడకిల్ జరనల్ లో పరచనరిించిన క్ానీ మీరు ఫలితాలు ఏ పరచనరణ లేదా పరద్రశనలో 
పతరు దాారా గురిి ించలేము. అయతే, మీ వెైద్య గమనికలు మీ అద్నపు అననమత్త లేకుిండా, అధ్య నిం సింబింధ్ిం 
పరజలు పునఃసమీక్షిసాి డ్్, మీరు ఈ అధ్య నింలో పాలగొ నేింద్నకు నిరణయించనకుింటారు ఉిండాలి. 
లేదా ఇమయెల్:  
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                                CONSENT FORM IN TELUGU 
 
 
                                  వెైద్య పరరక్షలనన పాలగొ నడానిక్ర సమమత్తించారు 
 
 సిడీ శీరిి క: డ్యాలిస్టస్ మరయిు డెైనమిక్ సమోననత్ కనననగుడ్్డులోని ఒతి్తడ ినిరణ యించనట-A క్ాి స్ స్కె్షనల్ 
అధ్య నిం ఉపయోగిించి సాధారణ వ్యకుి లపెై చివ్రి ద్శలోని మూత్రపటిండ్ వాయధి క్ాని మధ్నమేహ రోగులు సింబింధతి్ 
పల్్ ఆమిలటియయడ్ 
 
సిడీ సింఖయ: 
 
పారిిస్టపెింట్ యొకక పతరు: 
 
హాస్టిటల్ సింఖయ: 
 
పుటిి న / వ్యసన తేదీ (సింవ్త్్రాలలో): 
 
I_____________________________________________________________, 
 
  సన్ / ___________________________________ కుమారెి 
 
(ద్యచసే్ట టిక్ పటెటి లు) 
 
• ననేన సమాచారిం షటీ్ ఈ అధ్య నిం గురిించి నాకు అిందిించడానిక్ర చదివి ననేన కలిగి ఉనన అననమానాలనన 
వివ్రిించారు చసే్టన పరకటిసాి య. [ ] 
• ననేన కలడా ఈ అధ్య నింలో నా పాలగొ నడ్ిం పూరిి గా సాచఛింద్ మరియు నా సాధారణ చిక్రత్్ లేదా నా చటిపరమెైన 
కు పరభావిత్ిం లేకుిండా ఏ సమయింలోనెైనా పాలగొ నేింద్నకు క్ొనసాగిించడానిక్ర అననమత్త ఉపసింహరిించనక్ోవాలని ఉచిత్ 
అని అరథ ిం [ ] 
• ననేన కలడా పరరక్ష ఉచిత్ింగా కలడా అరథ ిం చసేనకునాననన [ ] 
• ననేన విచారణ ననిండి వనెక్రక కలడా అధ్య నిం స్టబబింది మరియు ఎథకి్్ కమిట ీసభ్ుయలు సింసాథ గత్ నా ఆరోగయ 
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రిక్ారుడ లనన కు నా అననమత్త అవ్సరిం లేద్న అని అరథ ిం. ననేన ఈ యాక్ె్స్ అింగరకరసిని నానరు [ ] 
• నా గురిి ింపునన మూడ్వ్ పారరిలకు విడ్్ద్ల ైన సమాచారిం లేక ఫలితాలు పరచనరిించిన బహ రొత్ిం చయెయబడ్ద్న అరథ ిం  [ ] 
• ననేన సాచఛింద్ింగా ఈ అధ్య నింలో పాలగొ నేింద్నకు మీరు అింగరకరసిని నానరు [ ] 
 
పతరు: 
 
సింత్కిం / బరర టనవలేు ముద్ర: 
 
తేద:ీ 
 
సాక్షి పతరు: 
 
అభ్యరిథ సింబింధ్ిం: 
 
తేదీ: 
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                                       ANNEXURE III 
                                     IRB REVIEW BOARD (IRB) APPROVAL 
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                                      ANNEXURE IV 
            
                                                PICTURE 1 
                       
                                               PICTURE 2                                  DCT 
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                                                                  PICTURE 3 
 
 
                                    
                                                                 PICTURE 4 
Sensor cap 
  Blue knob 
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                                                             PICTURE 7 
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